Metaraminol

In the clinical medication system for shock treatment, metaraminol is a vasoactive drug belonging to the α-adrenergic receptor agonist class. It can directly act on α receptors to constrict blood vessels, and meanwhile promote the release of norepinephrine to maintain mean arterial pressure. With the advantages of mild onset and long duration of action, it is a core drug for the first aid of hypotension caused by anaphylactic shock, cardiogenic shock, sepsis, and hypotension during intraspinal block anesthesia. Its applicable population covers acute and critically ill patients in multiple departments such as emergency department, ICU and anesthesiology department, and it can effectively reduce the risk of insufficient organ perfusion caused by hypotension.

The current global market size of metaraminol preparations is approximately USD 120 million, with China's market accounting for more than 45%, and the compound annual growth rate in the past 3 years reaching 8.7%. The demand growth is mainly related to the improvement of the emergency treatment system and the standardization of perioperative hypotension management. The domestic competitive landscape is dominated by generic drugs. Metaraminol has been included in the seventh batch of nationally organized drug centralized procurement, and the price of the selected preparations has dropped by more than 70%, which directly drives the continuous increase in demand for upstream API. At present, there are fewer than 5 domestic API suppliers with compliant registration, and the market supply concentration is relatively high.

The original research enterprise of metaraminol is Merck & Co., Inc. (US), with the original brand name Aramine. Its compound patent in the US market expired in the 1980s, and its core preparation patent in China expired in 2004. The mainstream dosage form of the original research product is injection, with two specifications of 10mg/1ml and 50mg/5ml. The original research product has been included in the FDA Reference Listed Drug Catalog, and the original research preparation has not been imported into China. At present, there are 13 metaraminol injection preparation varieties approved for marketing in China, and 3 valid A-status registration numbers have been announced on the CDE API registration platform, which can be directly associated with preparation applications. (Data as of April 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for metaraminol API. Most products support spot supply, and spot orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the full-process needs of API manufacturers and preparation R&D institutions for impurity research and quality control.